InMed Pharmaceuticals(INM)
VANCOUVER, British Columbia, CanadaPharmaceutical
Focus: InMed Pharmaceuticals is a public Canadian biotech focused on cannabinoid therapeutics and database development, currently in early-stage clinical programs targeting neurology and dermatology indications. The company is transitioning from commercial operations (BayMedica) toward drug development with minimal revenue generation.
Profile data last refreshed 9h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About InMed Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow InMed Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from InMed Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$5M
FY2025
Pipeline & Clinical Trials
PHASE_2
Clinical Trials (1)
NCT04908215INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa
Phase 2Help build intelligence for InMed Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.